Guidance and quality standards awaiting development | Guidance

Showing 61 to 70 of 360

Guidance and quality standards awaiting development
Title	Type
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance
Datopotamab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after osimertinib [TSID12418]	Technology appraisal guidance
Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]	Technology appraisal guidance
Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]	Technology appraisal guidance
DB-OTO for Hearing loss [ID6728]	Technology appraisal guidance
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]	Technology appraisal guidance
Delgocitinib for Chronic Hand Eczema [ID6688]	Technology appraisal guidance
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies [TSID12150]	Technology appraisal guidance
Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]	Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]	Technology appraisal guidance